Inclusion Criteria:  Participants who have initiated elagolix + Estradiol/Norethindrone Acetate (E2/NETA) in the last 30 days or less, or with planned initiation of elagolix + E2/NETA prescribed as part of standard of care treatment. Participants self-reporting heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). Participants are premenopausal (i.e., still report experiencing menses).  Exclusion Criteria:  Participants that report they are pregnant or planning to become pregnant in next 6 months.  Participants reporting a surgical history of:  Hysterectomy (with or without oophorectomy). Bilateral oophorectomy. Participants who have initiated elagolix + E2/NETA more than 30 days ago.